Breaks Categories: News

WednesdayFeb 14, 2024 10:49 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, including plans to advance two preclinical programs in Alzheimer's and age-related macular degeneration. Highlights of the report included that the company closed the 2023 calendar year in a cash position of $9.5 million and with 164% revenue growth in business subsidiary, BayMedica. “This period was another strong operational quarter for the company, as we expanded our pharmaceutical pipeline with…

Continue Reading

TuesdayFeb 13, 2024 3:50 pm

CannabisNewsBreaks – IBN’s CNW to Elevate Visibility for ZJ Events in 2024

CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of the 60+ brands within IBN (“InvestorBrandNetwork”), has announced its renewed partnership as the official newswire for ZJ Events in 2024. ZJ Events, an innovative organizer hosting multiple trade shows across the USA and South America every year, is set to deliver a captivating 2024 event series, featuring the BizCann Expo and Alternative Products Expo, the nation’s largest CBD and hemp event (formerly known as USA CBD Expo). Leveraging its extensive array of corporate-communications solutions, IBN aims to elevate the visibility of exhibitors, participants and the conferences among…

Continue Reading

TuesdayFeb 13, 2024 1:11 pm

CannabisNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q2 2024 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is releasing its financial results for Q2 2024, the period ended Dec. 31, 2023. Highlights of the report include a 512% increase in year-to-date revenue, which reached $1,540,000 compared to $301,000 in the same period in 2023; a strong consolidated balance sheet with $37 million in cash and liquid investments; and a year-to-date FY 2024 gross margin increase of 46% from 38% during the same period in 2023. In addition, the company reported that its 1st Detect subsidiary reentered detection and nondetection testing with the U.S. Transportation Security Administration (“TSA”) for cargo…

Continue Reading

FridayFeb 09, 2024 1:30 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles, primarily in the biotech industry. Most recently, she was vice president of Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she was a key player in the company’s initial public offering process;…

Continue Reading

TuesdayJan 30, 2024 12:56 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). The application covers HYPER-H23-1, the company’s upcoming planned U.S. phase 1b hypertension clinical trial of DehydraTECH-CBD. According to the announcement, the company had a successful pre-IND meeting with FDA officials. Following the guidance provided in that meeting regarding the development and filing of the IND, the company submitted the application on Jan. 29, 2024. The company will now wait 30 calendar days before initiating any clinical trials, in compliance with FDA guidelines.…

Continue Reading

ThursdayJan 25, 2024 2:08 pm

CannabisNewsBreaks — Boston Hemp Inc. Unveils New Product Designed to Redefine Cannabis Consumption

Boston Hemp, a pioneer in the cannabis industry, has launched its latest product: THCa Crumble Extract. According to the announcement, the groundbreaking new product showcases the company's commitment to providing consumers with high-quality, cutting-edge solutions for a diverse range of cannabis experiences. A carefully crafted concentrate, THCa Crumble Extract is designed to “harness” the power of tetrahydrocannabinolic acid (“THCa”) and provides the user with a full-spectrum, entourage effect during a premium, authentic cannabis encounter. THCa Crumble offers purity and potency as well as versatility, allowing users to explore various methods of consumption, including dabbing, vaporizing or incorporating the substance into…

Continue Reading

WednesdayJan 24, 2024 11:50 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Shares Company Update in Annual Shareholder Letter

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has released a shareholder letter from CEO Chris Bunka. In the letter, Bunka notes that near the end of 2023, 446 companies on the NASDAQ were trading under $1 and at risk of being delisted compared to almost none in 2021. Bunka stated that “it was a tough year for microcap companies, which are often too early stage to have profitable operations and withstand the harsh realities of the investment banking and finance industries: capital was much harder to come by in 2023 than at any time in recent years.” With…

Continue Reading

FridayJan 19, 2024 2:04 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview of InMed’s pharmaceutical pipeline in Alzheimer’s and ocular as well as a discussion about cannabinoids and their possible role in the treatment of Alzheimer’s. In addition, the chat will include a look at upcoming 2024…

Continue Reading

WednesdayJan 17, 2024 3:53 pm

CannabisNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Engages IBN for Corporate Communications Expertise

Astrotech (NASDAQ: ASTC) is an instrumentation company focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications around the world. The company today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Astrotech continues to expand its ATi Mass Spectrometer Technology into new markets and recently launched its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech also announced the formation of its newest wholly owned subsidiary, Pro-Control Inc., which has an…

Continue Reading

TuesdayJan 16, 2024 3:17 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies. In a recent human pilot study with seven volunteers, Lexaria demonstrated superior pharmacokinetic (“PK”) oral delivery performance of the DehydraTECH-enhanced glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). The positive results were sufficient to encourage a much more thorough and expanded investigation. The objective of the new planned studies, as detailed in the announcement, is…

Continue Reading